QIAGEN Exceeds Q2 2025 Outlook with 7% Sales Growth and Improved Profitability

QIAGEN exceeded its Q2 2025 outlook with net sales of $534mln (+7% actual rates) and adjusted diluted EPS of $0.60. Diagnostic solutions sales rose 11% CER, driven by QIAstat-Dx and QuantiFERON. The company increased its 2025 net sales outlook to +4-5% CER and reaffirmed the adjusted diluted EPS target of about $2.35 CER.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported solid Q2 2025 results, exceeding its previous outlook. The company's net sales rose by 7% to $534 million, with a 6% increase at constant exchange rates (CER), outperforming its prior guidance of at least 5% CER growth [1]. Adjusted diluted earnings per share (EPS) reached $0.60, surpassing the company's target of at least $0.60 CER [1].

The growth was driven by an 11% CER increase in diagnostic solutions sales, fueled by strong performances of QIAstat-Dx and QuantiFERON, which saw respective sales jumps of 41% and 11% CER [2]. Core sales, excluding discontinued products, also rose by 6% CER. The adjusted operating income margin improved to 29.9%, up by 1.5 percentage points from the previous year, reflecting efficiency gains and disciplined cost management [1].

In light of its strong performance, QIAGEN has revised its full-year 2025 net sales outlook to 4-5% CER growth, up from the previous estimate of about 4% CER growth [1]. The adjusted diluted EPS target remains at approximately $2.35 CER [1].

The company's results underscore its ability to navigate macroeconomic challenges, including U.S. and China import tariffs. QIAGEN's CEO, Thierry Bernard, attributed the performance to focused execution, strategic investments, and disciplined management. The company's CFO, Roland Sackers, noted that efficiency gains and cost management are supporting reinvestments in key initiatives while maintaining strong cash flow [1].

QIAGEN's financial performance is a testament to its robust position in the life sciences and molecular diagnostics markets. The company's ability to deliver strong results amidst challenging macroeconomic conditions is a positive indicator for investors.

References:
[1] https://finance.yahoo.com/news/qiagen-exceeds-outlook-q2-2025-200500949.html
[2] https://www.investing.com/news/earnings/qiagen-posts-strong-q2-raises-2025-sales-outlook-4171308